LUMOS PHARMA, INC. Quarterly Debt-to-equity in % from Q1 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Lumos Pharma, Inc. quarterly Debt-to-equity history and growth rate from Q1 2018 to Q3 2024.
  • Lumos Pharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 79.4 %, a 211% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 79.4 +53.9 +211% Sep 30, 2024
Q2 2024 52.3 +30.7 +143% Jun 30, 2024
Q1 2024 39.5 +21.3 +117% Mar 31, 2024
Q4 2023 31.1 +14.8 +90% Dec 31, 2023
Q3 2023 25.6 +11.2 +77.4% Sep 30, 2023
Q2 2023 21.5 +8 +59.1% Jun 30, 2023
Q1 2023 18.2 +5.05 +38.4% Mar 31, 2023
Q4 2022 16.4 +4.2 +34.5% Dec 31, 2022
Q3 2022 14.4 +2.76 +23.7% Sep 30, 2022
Q2 2022 13.5 +1.33 +10.9% Jun 30, 2022
Q1 2022 13.2 -7.88 -37.4% Mar 31, 2022
Q4 2021 12.2 -18.9 -60.8% Dec 31, 2021
Q3 2021 11.7 -34.2 -74.6% Sep 30, 2021
Q2 2021 12.2 -101 -89.3% Jun 30, 2021
Q1 2021 21.1 +243 Mar 31, 2021
Q4 2020 31.1 +61.4 Dec 31, 2020
Q3 2020 45.9 +84.9 Sep 30, 2020
Q2 2020 114 +395 Jun 30, 2020
Q1 2020 -222 -274 -528% Mar 31, 2020
Q4 2019 -30.2 -54.8 -223% Dec 31, 2019
Q3 2019 -39 -57 -317% Sep 30, 2019
Q2 2019 -281 -303 -1403% Jun 30, 2019
Q1 2019 52 +27.3 +111% Mar 31, 2019
Q4 2018 24.6 Dec 31, 2018
Q3 2018 18 Sep 30, 2018
Q2 2018 21.6 Jun 30, 2018
Q1 2018 24.7 Mar 31, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.